Biocon Q4 net profit falls 56.8% to ₹198.6 crore on exceptional charges
Synopsis
Biocon's Q4 profit collapsed 56.8% to ₹198.6 crore — not because the business is broken, but because exceptional charges, including those from the new labour code, hit hard. Revenue grew, leadership changed, and the company is calling it a 'pivotal year of integration'. The real question is whether FY27 normalises the bottom line.
Key Takeaways
Biocon reported a 56.8% YoY drop in Q4 consolidated net profit to ₹198.6 crore for the quarter ended 31 March 2026 .
Exceptional charges of ₹80.4 crore , including costs from the new labour code , weighed heavily on the bottom line.
Q4 consolidated revenue from operations rose to ₹4,516.6 crore from ₹4,417 crore in the year-ago period.
Full-year FY26 net profit fell to ₹368.8 crore from ₹1,429.4 crore in FY25; annual revenue climbed to ₹16,927 crore .
Shreehas Tambe took charge as CEO and Managing Director from 1 April 2026 ; Kedar Upadhye appointed as CFO.
Board recommended a final dividend of 50 paise per share (face value ₹5 ) for FY26, subject to shareholder approval.
Biocon Limited on Friday, 8 May 2026, reported a 56.8% year-on-year decline in consolidated net profit to ₹198.6 crore for the fourth quarter ended 31 March 2026, dragged by exceptional expenses — including charges arising from the implementation of the new labour code. The biotechnology major had posted a consolidated net profit of ₹459.4 crore in the corresponding quarter of the previous financial year, according to a regulatory filing.
Revenue Rises Despite Profit Pressure
Despite the sharp bottom-line decline, Biocon's consolidated revenue from operations grew to ₹4,516.6 crore in Q4 FY26, up from ₹4,417 crore in the year-ago quarter. Total expenses for the period, however, rose to ₹4,241.2 crore compared to ₹3,987.5 crore in the same quarter last year, squeezing margins considerably.
Exceptional Items Weigh on the Quarter
The company disclosed an exceptional item outgo of ₹80.4 crore during the quarter under various heads, with the new labour code implementation cited as a key contributor to the one-time impact. Such exceptional charges are typically non-recurring but can significantly distort a quarter's reported profitability. This is notably the second consecutive quarter in which Biocon has flagged integration and transition-related costs as a drag on earnings.
Full-Year Performance: Profit Slump, Revenue Climb
For the full financial year FY2025-26, Biocon's consolidated net profit dropped sharply to ₹368.8 crore from ₹1,429.4 crore in FY25 — a decline of nearly 74% on an annual basis. In contrast, annual consolidated revenue from operations climbed to ₹16,927 crore from ₹15,261.7 crore in the previous fiscal, reflecting underlying business growth even as profitability came under pressure.
Leadership Speaks: 'Resilience and Disciplined Execution'
Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, said the company ended FY26 on a strong note despite operating in a challenging geopolitical environment.
Point of View
But stripping out the exceptional items reveals a company whose revenue engine is actually accelerating — ₹16,927 crore in FY26 versus ₹15,261.7 crore in FY25. The deeper concern is that the annual profit erosion, from ₹1,429.4 crore to ₹368.8 crore, goes well beyond one quarter's exceptional charges, suggesting that integration costs and margin compression are structural, not episodic. The leadership transition — a new CEO and CFO simultaneously — adds execution risk at precisely the moment Biocon needs stability. Investors will be watching whether FY27 guidance, once issued, reflects genuine normalisation or another round of 'pivotal year' hedging.
NationPress
9 Nov 2026
Frequently Asked Questions
Why did Biocon's Q4 profit fall so sharply?
Biocon's Q4 FY26 consolidated net profit fell 56.8% to ₹198.6 crore primarily due to exceptional charges of ₹80.4 crore, including costs arising from the implementation of the new labour code. Total expenses for the quarter also rose to ₹4,241.2 crore from ₹3,987.5 crore in the year-ago period.
How did Biocon's revenue perform in Q4 FY26?
Despite the profit decline, Biocon's consolidated revenue from operations rose to ₹4,516.6 crore in Q4 FY26, up from ₹4,417 crore in the same quarter last year, indicating continued business growth.
What was Biocon's full-year FY26 financial performance?
For the full year FY2025-26, Biocon's consolidated net profit dropped to ₹368.8 crore from ₹1,429.4 crore in FY25, while annual revenue from operations grew to ₹16,927 crore from ₹15,261.7 crore in the previous fiscal.
Who are Biocon's new top executives?
Shreehas Tambe assumed charge as CEO and Managing Director of Biocon from 1 April 2026, while Kedar Upadhye has been appointed as the company's Chief Financial Officer, marking a significant leadership transition for the biotechnology major.
What dividend has Biocon declared for FY26?
Biocon's board has recommended a final dividend of 50 paise per equity share with a face value of ₹5 each for FY26. The dividend is subject to shareholders' approval at the upcoming annual general meeting.
